|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||20.10 / 300.00|
At some point Tilray is going to suffer a very ugly drop, but trying to guess when is like trying to time a slot machine.
"The problem with the world is that fools and fanatics are always so certain of themselves and wiser people so full of doubts." -- Bertrand Russell The interest rate for a Tilray borrow is now over 264% -- that's annually! Be forewarned.
The cannabis company has gained DEA approval to import a cannabinoid drug into the U.S.
* Tilray is now a sideshow of classic speculative activity * Neither go short nor go long TLRY * Ignore TLRY and move on Pot stock Tilray, Inc. is trading at $215/share (+$60 in premarket trading). The short squeeze is reminiscent of Robert Wilson'...
Expect more companies to join Coca-Cola, Molson Coors and Constellation Brands in checking out the market.
It is likely that value buyers will be looking for entry soon as the stock tests the $240 area.
The latest reports about Coke looking into cannabis confirms a broader industry trend.
If you don't have a steady diet of losing trades you probably aren't trading at optimal levels.
Wild speculation in pot stocks and IPO names was a notable characteristic this week.
This morning the futures (S&P and Nasdaq) are, as is the custom, higher. The markets continue to ignore a number of cautionary signposts/macroeconomic events/concerns and are benefiting from the float shrink of 5-7 years of corporate share buybacks,...
The pot stock is up some 500% even though probably everyone knows it's not worth that much.
Pot stock Tilray, Inc. is trading at $123/share (+$19 on the day). The short squeeze is reminiscent of Robert Wilson's legendary short in Resorts International. The price action in Resorts, Tilray, Tesla , etc., are examples of why my basic and firs...
Not every cannabis stock was strong on Wednesday. One significant Canadian name sure was though.
The underlying action, particularly the weakness in the technology sector, is reason for concern.
Facebook still needs to prove to the market that it can regain operational footing.
Several cannabis companies are planning to go public this fall.
Tilray reported a 95% jump in second-quarter revenue to $9.7 million, ahead of the Wall Street estimate of $9 million, in its first earnings release since it went public on July 19.
AMD continues to surge, after significant year-over-year improvements almost everywhere.
This is simply a short-term thesis that the cannabis rally will cool this week.
Seasonality hasn't mattered in a number or years so why should light volume new highs be an issue?
The Nasdaq-listed provider of medical marijuana will compete with other firms as Canada opens itself to general adult use of marijuana this fall.
Expect several more firms to list on stock exchanges this year.